Current treatment of follicular lymphoma
Bonnet, C.; Beguin, Y.; Deprijck, B.; de Leval, L.; Fillet, G.
Revue Medicale Suisse 5(214): 1663-1667
2009
ISSN/ISBN: 1660-9379 PMID: 19772198 Document Number: 11885
After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the presence of clinical and/or biology aggressiveness. These patients should be treated by rituximab (Mab-Thera) associated to polychemotherapy comprising cyclophosphamide, vincristine and prednisone. After this therapy, the benefit of rituximab in maintenance has to be confirmed. Autologous stem cell transplantation is now reserved for young patients in first relapse. Allogenic stem cell transplantation is also an interesting option. The other therapeutic options comprise radio-immunotherapy with 90Y ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade).
Document emailed within 1 workday
